Matt Zorn’s Legal Advocacy Spurs Major Shift in U.S. Drug Policy Reform

Matt Zorn, a prominent litigator turned policymaker, is emerging as a central figure in the transformation of American drug policy, according to a recent analysis by High Times. Zorn's decade-long career challenging federal agencies over controlled substances law has positioned him at the forefront of efforts to modernize regulations around cannabis and psychedelics. His transition from courtroom battles to government leadership echoes the trajectory of historic civil rights figures and signals a new phase for drug policy reform

Zorn, along with legal partner Shane Pennington, has spent years representing doctors, researchers, and patients navigating regulatory ambiguities in the realm of controlled substances. Their strategic litigation exposed inconsistencies between government prohibitions and enforcement, forcing courts to confront the limitations and contradictions in federal drug policy. "Zorn became a central figure in a style of drug policy advocacy that relied less on politics and more on strategic litigation to test the limits of federal power," the report notes

In May of last year, Zorn was appointed Deputy General Counsel at the Department of Health and Human Services (HHS) by Secretary Robert F. Kennedy Jr., marking a pivotal shift from external legal challenges to shaping policy from within. Zorn played a key role in drafting President Trump's Executive Order on psychedelics, just years after having sued HHS to release the scientific review that underpinned the recent cannabis rescheduling decision. This marks a remarkable transition, as the same litigator who once challenged federal agencies now crafts their drug policy initiatives

High Times draws a striking comparison between Zorn and Thurgood Marshall, the legendary civil rights advocate who leveraged litigation to force institutional change before joining the federal government and ultimately the Supreme Court. Both figures exemplify how strategic legal advocacy, in tandem with grassroots activism, can drive sweeping social reform. As the article highlights, "Their careers point to a broader lesson about how social movements succeed in the United States: through the interplay of grassroots pressure, disciplined legal advocacy, and, eventually, participation within government to carry reforms forward from within."

The article also cautions that moments of major policy transition can fracture social movements, referencing the splintering of the civil rights coalition late in President Johnson’s term and the subsequent entrenchment of restrictive drug laws under President Nixon. As the cannabis and psychedelic communities celebrate recent victories, internal division and poorly managed implementation could risk stalling progress for years. The report urges advocates to "focus on building a new, durable epistemological foundation for plant medicine in this country as a category of legitimate therapeutic value, and avoiding the destructive infighting that has weakened other social movements at precisely the moments of greatest opportunity."

From an OG Lab perspective, Zorn’s ascent demonstrates the critical role that disciplined legal strategy and insider participation play in advancing drug policy reform. As the U.S. moves forward with cannabis rescheduling and expanded psychedelic research, industry stakeholders should prioritize unity and robust regulatory frameworks to sustain momentum. This period of rapid change is likely to shape the landscape of plant medicine for decades, and the emergence of legal advocates like Zorn in policymaking roles could redefine the future of controlled substances law